Objective: The aim of this prospective study was to compare the efficacy of the first-line lansoprazole-based sequential therapy and concomitant therapy (lansoprazole, amoxicillin, clarithromycin and metronidazole) for Helicobacter pylori (H. pylori) eradication.
Methods: A total of 169 patients with H. pylori infection were randomly assigned to either the sequential therapy group (n = 85) or the concomitant therapy group (n = 84). A follow-up endoscopy or urea breath test was examined at least 12 weeks after eradication.
Results: Comparable H. pylori eradication rate was observed in both the sequential therapy and concomitant therapy groups by either intention-to-treat analysis [sequential 80.0% (68/85) vs concomitant 88.1% (74/84); P = 0.27] or per protocol analysis [sequential, 85.3% (64/75) vs concomitant, 94.6% (70/74); P = 0.60]. Adverse effects were reported and good compliance was observed in both groups (P = 0.72). Although dual antibiotics resistance affected the therapeutic efficacy of sequential therapy (P = 0.03), not concomitant therapy (P = 0.74), it was not an independent factor for predicting the treatment outcome.
Conclusion: First-line lansoprazole-based sequential and concomitant therapy were well-tolerated and comparable in terms of their H. pylori eradication rate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1751-2980.2012.00575.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Is San Diego California on Track to Reach HCV Elimination? A Modeling Analysis of Combination Prevention Strategies.
Viruses
November 2024
Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA.
In 2020, the in the county of San Diego (COSD) was launched, a private-public joint endeavor between the COSD and the American Liver Foundation. We use epidemic modeling to assess whether the COSD is on track to reach its elimination targets (80% reduction in incidence, 65% reduction in hepatitis C virus (HCV)-related mortality by 2030 compared to 2015) and what intervention scale-up may be required. We adapted a previously developed dynamic, deterministic model of HCV transmission and disease progression among adults in the COSD, stratified by risk, age, gender, and human immunodeficiency virus (HIV) status.
View Article and Find Full Text PDFPharmacokinetic Interaction Between Olaparib and Regorafenib in an Animal Model.
Pharmaceutics
December 2024
Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Rokietnicka 3, 60-806 Poznań, Poland.
Background: Olaparib (OLA) and regorafenib (REG) are metabolized by the CYP3A4 isoenzyme of cytochrome P450. Both drugs are also substrates and inhibitors of the membrane transporters P-glycoprotein and BCRP. Therefore, the potential concomitant use of OLA and REG may result in clinically relevant drug-drug interactions.
View Article and Find Full Text PDFConcomitant Inhibition and Collaring of Dual-Species Biofilms Formed by and by Triazole Based Small Molecule Inhibitors.
Pharmaceutics
December 2024
Department of Chemistry, College of Science, University of Jeddah, Jeddah 21589, Saudi Arabia.
Background/objectives: Biofilm-associated infections, particularly those involving Candida auris and Staphylococcus aureus, pose significant challenges in clinical settings due to their resilience and resistance to conventional treatments. This study aimed to synthesize novel triazole derivatives containing a piperazine ring via click chemistry and evaluate their efficacy in disrupting biofilms formed by these pathogens.
Methods: Triazole derivatives were synthesized using click chemistry techniques.
Concomitant Potentially Contagious Factors Detected in Poland and Regarding Strains, Etiological Agents of Keratitis in Humans.
Microorganisms
November 2024
Laser Eye Microsurgery Centre Clinic of Prof. Jerzy Szaflik, 00-215 Warsaw, Poland.
Background: Diseases in humans caused by amphizoic amoebae that can result in visual impairment and even blindness, have recently been identified more frequently worldwide. Etiologically complex incidents of keratitis, including those connected with strains detected in Poland, were evaluated in this study.
Methods: Corneal samples from cases resistant to antimicrobial therapy assessed for epidemiological, microbiological and parasitological aspects were investigated by phase-contrast microscope, slit lamp and by confocal microscopy.
Evaluating Drug Interaction Risks: Nirmatrelvir & Ritonavir Combination (PAXLOVID) with Concomitant Medications in Real-World Clinical Settings.
Pathogens
November 2024
Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague, Czech Republic.
Background: This research article delves into the battle against the COVID-19 pandemic, focusing on the efficacy and, particularly, the safety of the combination of nirmatrelvir with ritonavir, which is found in the pharmaceutical product Paxlovid. This study aims to analyze the potential interactions of commonly prescribed medicinal products with Paxlovid, shedding light on its utilization in specific medical fields.
Methods: Prescription data from the Czech Republic's Institute of Health Information and Statistics (IHIS CR) was analyzed, covering 4 million COVID-19 patients and 87.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!